Pharma Sector

Indian stock markets ended lower for the third consecutive session on October 22, with the Sensex declining 460 points and the Nifty slipping below 22,700. Media, FMCG, IT and energy stocks led sectoral losses, while rising Brent crude prices and a sell-off across Asian markets added to investor concerns.

Sensex fell 876 points to 73,852.90 and Nifty declined 1.11% to 22,888.95 on October 19, 2026. Banking and IT stocks led losses amid earnings concerns, elevated crude oil prices and foreign investor outflows.

Cupid shares hit a record high of ₹344.90 after entering the Nifty Smallcap 250 index. Nuvama estimates potential passive inflows of around $10 million, while strong Q1 earnings and upgraded guidance add to investor interest.

The Indian stock market is under pressure as geopolitical tensions, rising crude oil prices, higher US Treasury yields, rupee weakness and foreign investor selling trigger a broad-based sell-off in Nifty and Sensex.

Nifty Today: Indian markets faced heavy selling pressure as Nifty fell 370 points, crude oil surged above $105 and India VIX jumped 25%. US bond yields and geopolitical tensions added to market volatility.

Indian benchmark indices ended higher on September 10, 2026, snapping a three-session losing streak. Nifty and Sensex gained 0.20% and 0.19%, respectively, led by banking and financial stocks, while crude oil above $100, rupee weakness and pressure in auto and metal stocks kept gains limited.

Indian markets ended lower on Thursday, with the Nifty 50 falling 41 points and the Sensex declining 417 points amid sharp expiry-day volatility. Banking stocks gained after the RBI reported $136.38 billion in foreign currency inflows, while Solar Industries rallied on acquisition buzz.

Indian benchmark indices ended marginally lower on September 1, 2026, extending losses for a second consecutive session. The Nifty 50 fell 0.10% to 24,055.80, while the Sensex declined 0.02% to 76,944.28. Renewed US-Iran tensions and Brent crude crossing $91 a barrel pressured banking, auto, realty and pharma stocks, while gains in ITC, IT and telecom counters capped the downside.

Symbiotec Pharmalab shares made a flat debut at ₹988 on the NSE, matching the IPO issue price. The stock later rallied nearly 11% to ₹1,092.40, after touching an intraday high of ₹1,098. The IPO was subscribed 71.26 times, with QIBs leading demand at 172.03 times.

The MSCI index reshuffle takes effect on September 1, bringing Laurus Labs, Lenskart, Adani Energy Solutions and Groww into focus. Here’s what the changes mean, why global funds may buy or sell these stocks, how Reliance Industries is affected, and why the new Closing Auction Session could lead to higher volatility.